This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
11-13 November 2025
Congress Center BaselBasel, Switzerland

Dr. Thomas Langenickel, MD, PhD
Chief Medical Officer at Ethris GmbH
Speaker

Profile

Dr. Langenickel is Chief Medical Officer at Ethris. Prior to his current role, Dr. Langenickel gained two decades of pharmaceutical industry experience in drug discovery, translational medicine and clinical drug development including regulatory submissions in respiratory, cardiovascular, and metabolic diseases, resulting in three marketed medicines for the treatment of heart failure and asthma. Dr. Langenickel obtained his M.D. and Ph.D. from the Humboldt University of Berlin, Germany, trained in Clinical Pharmacology and Internal Medicine/Cardiology at the Max-Delbrück Center for Molecular Medicine and the Charité in Berlin, Germany, and completed a post-doctoral fellowship in vascular biology at the National Heart, Lung, and Blood Institute, NIH, USA.

Agenda Sessions

  • Development of ETH47 for the Treatment of Asthma

    14:00